Aura Biosciences, Inc. (NASDAQ:AURA) Insider Sells $19,638.50 in Stock

Aura Biosciences, Inc. (NASDAQ:AURA) insider Janet Jill Hopkins sold 2,534 shares of Aura Biosciences stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $7.75, for a total transaction of $19,638.50. Following the completion of the transaction, the insider now directly owns 269,794 shares of the company’s stock, valued at $2,090,903.50. This trade represents a 0.93 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Aura Biosciences Stock Down 0.3 %

AURA opened at $7.63 on Friday. The stock has a market capitalization of $381.12 million, a price-to-earnings ratio of -4.41 and a beta of 0.29. The firm has a 50 day moving average price of $8.01 and a 200-day moving average price of $8.74. Aura Biosciences, Inc. has a twelve month low of $6.63 and a twelve month high of $12.38.

Institutional Investors Weigh In On Aura Biosciences

A number of hedge funds have recently added to or reduced their stakes in the stock. Charles Schwab Investment Management Inc. boosted its stake in shares of Aura Biosciences by 2.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 138,356 shares of the company’s stock worth $1,233,000 after buying an additional 3,612 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Aura Biosciences by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 1,012,799 shares of the company’s stock valued at $8,327,000 after acquiring an additional 3,972 shares during the period. Wells Fargo & Company MN boosted its position in Aura Biosciences by 27.3% in the fourth quarter. Wells Fargo & Company MN now owns 27,623 shares of the company’s stock worth $227,000 after purchasing an additional 5,930 shares during the last quarter. BNP Paribas Financial Markets bought a new stake in shares of Aura Biosciences during the 4th quarter valued at about $50,000. Finally, Bank of America Corp DE increased its position in shares of Aura Biosciences by 20.5% during the 4th quarter. Bank of America Corp DE now owns 51,286 shares of the company’s stock valued at $422,000 after purchasing an additional 8,709 shares during the last quarter. 96.75% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. Lifesci Capital upgraded shares of Aura Biosciences to a “strong-buy” rating in a report on Friday, January 31st. HC Wainwright reissued a “buy” rating and issued a $22.00 target price on shares of Aura Biosciences in a report on Thursday, November 14th. Five research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $23.00.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.